The purpose of this clinical trial is to evaluate the long-term efficacy and safety of low-dose oral corticosteroids combined with cyclophosphamide therapy and low-dose corticosteroids monotherapy, on a background of maximal RAS inhibitor therapy, for IgA nephropathy with stage 3 or 4 chronic kidney disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
208
RAS blockade as much as tolerated or allowed
RAS blockade as much as tolerated or allowed
AFMMU
Xi'an, China
RECRUITINGCombined event
40% decrease in eGFR, ESRD or death due to kidney disease
Time frame: up to 6 years
Proteinuria remission at 6, 12 months and total follow-up period
Proteinuria remission
Time frame: up to 6 years
Hematuria remission at 6, 12 months and total follow-up period
Hematuria remission
Time frame: up to 6 years
The composite of 30% decrease in eGFR, ESRD and all cause death
Time frame: up to 6 years
The composite of 40% decrease in eGFR, ESRD and all cause death
Time frame: up to 6 years
The composite of 50% decrease in eGFR, ESRD and all cause death
Time frame: up to 6 years
Annual eGFR decline rate
Time frame: up to 6 years
30% decrease in eGFR
Time frame: up to 6 years
40% decrease in eGFR
Time frame: up to 6 years
50% decrease in eGFR
Time frame: up to 6 years
ESRD
Time frame: up to 6 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
All cause death
Time frame: up to 6 years